(Q42237242)

19 October 2017

title

Shot in the HAART: vaccine therapy for HIV. (English)

1 reference

19 October 2017

1

Merlin L Robb

1 reference

19 October 2017

2

Jerome H Kim

1 reference

19 October 2017

publication date

11 February 2014

1 reference

Lancet Infectious Diseases

19 October 2017

published in

1 reference

19 October 2017

volume

14

1 reference

19 October 2017

issue

4

1 reference

19 October 2017

page(s)

259-260

1 reference

Vaccine therapy for HIV: a historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Immune interventions in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

CD4+ count-guided interruption of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970331-1

7 January 2021

10.1016/S1473-3099(13)70331-1

Identifiers

DOI

1 reference

19 October 2017

1 reference